Esophageal cancer Locally advanced esophageal cancer
Conditions
Interventions
Chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R)
Sponsors
Miyata Hiroshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 The first occurrence of thoracic esophageal cancer for which diagnosis of squamous cell carcinoma (including adenosquamous cell carcinoma and basal cell carcinoma) was obtained by histology Example (including cases that partially affect the cervical esophagus or abdominal esophagus) 2 Thoracic esophagus cancer (cT4 esophagus cancer) with clinical involvement of the aorta or trachea without curative organ metastasis. Abdominal lymph node (No. 1, 2, 3, 7, 9) metastasis-positive cases are eligible. 3 over 20 years old and under 80 years old 4 PS (ECOG) 0-1 5 There is no prior treatment for esophageal cancer. However, endoscopic resection (pT1a, ly0, v0) obtained with curative resection is acceptable. 6 No history of radiation exposure to neck and chest 7 Main organ function is maintained 8 Patients who have obtained consent from the patient
Exclusion criteria
Exclusion criteria: 1 Chemoradiotherapy is difficult to perform due to abnormalities in major organs (brain, heart, lung, liver, kidney) 2 active double cancer (However, cases that can be cured by treatment are eligible) 3 Perforation or penetration case by primary lesions or lymph nodes 4 Cases with a history of serious drug hypersensitivity 5 pregnant women, lactating women and women with the possibility and intention of pregnancy 6 Cases with severe pulmonary emphysema or pulmonary fibrosis or interstitial pneumonia recognized by lung function test, CT 7 HBs antigen positive cases 8 Cases deemed inappropriate by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse effect | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment completion rate, complete response rate, treatment response rate, overall survival, salvage surgery rate | — |
Contacts
Public ContactTakashi Kanemura
Osaka International Cancer Institute
Outcome results
None listed